<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Case Studies - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765115033437">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html">Overview</a></li>
                <li><a href="selection-criteria.html">Selection Criteria</a></li>
                <li><a href="outcomes.html">Clinical Outcomes</a></li>
                <li><a href="tools.html">Tools</a></li>
                <li><a href="faq.html">FAQ</a></li>
                <li><a href="glossary.html">Glossary</a></li>
                <li><a href="case-studies.html" class="active">Case Studies</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Case Studies
            </div>

            <h1>Clinical Case Studies</h1>

            <section class="section">
                <p>The following case studies illustrate how prognostic scoring systems and patient selection criteria are applied in real-world clinical scenarios. Each case demonstrates the decision-making process and expected outcomes for different patient profiles.</p>
            </section>

            <!-- Case 1: Ideal Candidate -->
            <section class="section case-study">
                <div class="case-header excellent">
                    <h2>Case 1: Ideal Candidate for LT</h2>
                    <span class="case-badge">EXCELLENT CANDIDATE</span>
                </div>

                <div class="case-content">
                    <h3>Patient Presentation</h3>
                    <p><strong>Patient:</strong> 52-year-old female with synchronous liver-only colorectal metastases</p>
                    
                    <div class="case-table">
                        <table class="data-table">
                            <tr>
                                <th>Parameter</th>
                                <th>Value</th>
                                <th>Significance</th>
                            </tr>
                            <tr>
                                <td><strong>Primary Tumor</strong></td>
                                <td>Right colon, T3N0M1</td>
                                <td>Node-negative primary (favorable)</td>
                            </tr>
                            <tr>
                                <td><strong>Metastases</strong></td>
                                <td>3 liver lesions, largest 4.2 cm</td>
                                <td>Multiple lesions but small size</td>
                            </tr>
                            <tr>
                                <td><strong>CEA Level</strong></td>
                                <td>32 ng/mL</td>
                                <td>Mildly elevated (< 80)</td>
                            </tr>
                            <tr>
                                <td><strong>Performance Status</strong></td>
                                <td>ECOG 0</td>
                                <td>Fully active</td>
                            </tr>
                            <tr>
                                <td><strong>Comorbidities</strong></td>
                                <td>None significant</td>
                                <td>No contraindications</td>
                            </tr>
                        </table>
                    </div>

                    <h3>Prognostic Assessment</h3>
                    <table class="data-table">
                        <tr>
                            <th>Scoring System</th>
                            <th>Score</th>
                            <th>Risk Category</th>
                            <th>Expected 5-Year OS</th>
                        </tr>
                        <tr class="favorable">
                            <td><strong>Oslo Score</strong></td>
                            <td>0</td>
                            <td>Favorable</td>
                            <td>80-92%</td>
                        </tr>
                        <tr class="favorable">
                            <td><strong>FCRS</strong></td>
                            <td>1</td>
                            <td>Favorable</td>
                            <td>75-80%</td>
                        </tr>
                        <tr class="favorable">
                            <td><strong>PET-MTV</strong></td>
                            <td>45 cm³</td>
                            <td>Favorable (< 70)</td>
                            <td>63.6%</td>
                        </tr>
                    </table>

                    <h3>Molecular Profile</h3>
                    <ul>
                        <li><strong>BRAF:</strong> Wild-type (✓ eligible)</li>
                        <li><strong>KRAS:</strong> Wild-type (favorable)</li>
                        <li><strong>TP53:</strong> Wild-type (favorable)</li>
                        <li><strong>MSI:</strong> Microsatellite stable (✓ eligible)</li>
                        <li><strong>RAS/TP53 co-mutations:</strong> Absent (favorable)</li>
                    </ul>

                    <h3>Clinical Course</h3>
                    <p><strong>Bridging Therapy:</strong> 6 months of FOLFOX + bevacizumab</p>
                    <ul>
                        <li>Excellent response: 80% reduction in tumor burden</li>
                        <li>CEA normalized to 8 ng/mL</li>
                        <li>No disease progression</li>
                        <li>Excellent tolerance to chemotherapy</li>
                    </ul>

                    <h3>Treatment Decision</h3>
                    <div class="decision-box">
                        <p><strong>Recommendation:</strong> PROCEED WITH LIVER TRANSPLANTATION</p>
                        <p><strong>Rationale:</strong> All favorable prognostic factors; excellent response to bridging chemotherapy; no exclusion criteria; expected 5-year OS 80-90%.</p>
                    </div>

                    <h3>Outcome</h3>
                    <p><strong>Surgical Course:</strong> Deceased donor liver transplantation performed without complications</p>
                    <ul>
                        <li><strong>Operative time:</strong> 4.5 hours</li>
                        <li><strong>Blood loss:</strong> 800 mL</li>
                        <li><strong>Graft function:</strong> Excellent immediate function</li>
                        <li><strong>ICU stay:</strong> 2 days</li>
                        <li><strong>Hospital stay:</strong> 10 days</li>
                    </ul>

                    <p><strong>Follow-up (36 months post-LT):</strong></p>
                    <ul>
                        <li>No recurrence detected</li>
                        <li>Excellent graft function (INR 1.1, bilirubin 0.8, albumin 4.2)</li>
                        <li>Stable immunosuppression (tacrolimus level 8-10 ng/mL)</li>
                        <li>No episodes of acute rejection</li>
                        <li>Excellent quality of life</li>
                    </ul>

                    <p><strong>Key Learning Point:</strong> Ideal candidates with favorable prognostic factors achieve excellent long-term outcomes comparable to traditional LT indications (HCC within Milan criteria).</p>
                </div>
            </section>

            <!-- Case 2: Borderline Candidate -->
            <section class="section case-study">
                <div class="case-header acceptable">
                    <h2>Case 2: Borderline Candidate</h2>
                    <span class="case-badge">ACCEPTABLE CANDIDATE</span>
                </div>

                <div class="case-content">
                    <h3>Patient Presentation</h3>
                    <p><strong>Patient:</strong> 58-year-old male with metachronous liver-only colorectal metastases</p>
                    
                    <div class="case-table">
                        <table class="data-table">
                            <tr>
                                <th>Parameter</th>
                                <th>Value</th>
                                <th>Significance</th>
                            </tr>
                            <tr>
                                <td><strong>Primary Tumor</strong></td>
                                <td>Sigmoid colon, T3N2M0 (3 years prior)</td>
                                <td>Node-positive primary</td>
                            </tr>
                            <tr>
                                <td><strong>Disease-Free Interval</strong></td>
                                <td>36 months</td>
                                <td>Long interval (favorable)</td>
                            </tr>
                            <tr>
                                <td><strong>Metastases</strong></td>
                                <td>6 liver lesions, largest 6.0 cm</td>
                                <td>Multiple lesions, borderline size</td>
                            </tr>
                            <tr>
                                <td><strong>CEA Level</strong></td>
                                <td>85 ng/mL</td>
                                <td>Elevated (> 80)</td>
                            </tr>
                            <tr>
                                <td><strong>Performance Status</strong></td>
                                <td>ECOG 1</td>
                                <td>Restricted to light activity</td>
                            </tr>
                        </table>
                    </div>

                    <h3>Prognostic Assessment</h3>
                    <table class="data-table">
                        <tr>
                            <th>Scoring System</th>
                            <th>Score</th>
                            <th>Risk Category</th>
                            <th>Expected 5-Year OS</th>
                        </tr>
                        <tr class="intermediate">
                            <td><strong>Oslo Score</strong></td>
                            <td>2</td>
                            <td>Intermediate</td>
                            <td>~60%</td>
                        </tr>
                        <tr class="intermediate">
                            <td><strong>FCRS</strong></td>
                            <td>2</td>
                            <td>Favorable</td>
                            <td>75-80%</td>
                        </tr>
                        <tr class="intermediate">
                            <td><strong>PET-MTV</strong></td>
                            <td>75 cm³</td>
                            <td>Intermediate (≥ 70)</td>
                            <td>25%</td>
                        </tr>
                    </table>

                    <h3>Molecular Profile</h3>
                    <ul>
                        <li><strong>BRAF:</strong> Wild-type (✓ eligible)</li>
                        <li><strong>KRAS:</strong> G12V mutation (unfavorable)</li>
                        <li><strong>TP53:</strong> Wild-type (favorable)</li>
                        <li><strong>MSI:</strong> Microsatellite stable (✓ eligible)</li>
                        <li><strong>RAS/TP53 co-mutations:</strong> Absent (favorable)</li>
                    </ul>

                    <h3>Clinical Course</h3>
                    <p><strong>Bridging Therapy:</strong> 9 months of FOLFOXIRI + cetuximab (anti-EGFR for KRAS wild-type would be preferred, but patient has KRAS mutation)</p>
                    <ul>
                        <li>Partial response: 40% reduction in tumor burden</li>
                        <li>CEA decreased to 45 ng/mL (still elevated)</li>
                        <li>Stable disease after 6 months</li>
                        <li>Grade 2 neuropathy from oxaliplatin</li>
                    </ul>

                    <h3>Multidisciplinary Discussion</h3>
                    <div class="discussion-box">
                        <p><strong>Key Questions:</strong></p>
                        <ul>
                            <li>Is intermediate Oslo Score (2) acceptable given other factors?</li>
                            <li>Does high PET-MTV (75 cm³) outweigh favorable FCRS?</li>
                            <li>Should extended bridging therapy be considered?</li>
                            <li>What is patient's understanding of outcomes and risks?</li>
                        </ul>
                        <p><strong>Team Consensus:</strong> Acceptable candidate for LT with careful patient counseling about intermediate prognosis. Extended bridging therapy recommended to optimize disease control.</p>
                    </div>

                    <h3>Treatment Decision</h3>
                    <div class="decision-box">
                        <p><strong>Recommendation:</strong> PROCEED WITH LIVER TRANSPLANTATION AFTER EXTENDED BRIDGING</p>
                        <p><strong>Rationale:</strong> Intermediate risk but no absolute contraindications. Extended bridging therapy (additional 3-6 months) recommended to improve metabolic tumor volume and CEA level. Expected 5-year OS 50-70%.</p>
                    </div>

                    <h3>Outcome</h3>
                    <p><strong>Extended Bridging Therapy (3 additional months):</strong></p>
                    <ul>
                        <li>Additional 20% reduction in tumor burden</li>
                        <li>CEA decreased to 28 ng/mL</li>
                        <li>PET-MTV improved to 62 cm³ (now favorable)</li>
                        <li>Completion of bridging therapy after 12 months total</li>
                    </ul>

                    <p><strong>Surgical Course:</strong> Living donor liver transplantation (sister donor)</p>
                    <ul>
                        <li><strong>Graft type:</strong> Right lobe LDLT</li>
                        <li><strong>Operative time:</strong> 6 hours</li>
                        <li><strong>Graft function:</strong> Good initial function</li>
                        <li><strong>Hospital stay:</strong> 14 days</li>
                    </ul>

                    <p><strong>Follow-up (24 months post-LT):</strong></p>
                    <ul>
                        <li><strong>12 months:</strong> Pulmonary metastasis detected (1.2 cm)</li>
                        <li><strong>Treatment:</strong> Thoracoscopic resection performed</li>
                        <li><strong>18 months:</strong> Peritoneal nodule detected</li>
                        <li><strong>Treatment:</strong> Systemic chemotherapy restarted (FOLFOX)</li>
                        <li><strong>24 months:</strong> Stable disease on chemotherapy; good graft function</li>
                    </ul>

                    <p><strong>Key Learning Point:</strong> Borderline candidates benefit from extended bridging therapy to optimize disease control. Even with recurrence, median OS after relapse is 37.1 months, providing opportunity for salvage therapy.</p>
                </div>
            </section>

            <!-- Case 3: Poor Candidate -->
            <section class="section case-study">
                <div class="case-header poor">
                    <h2>Case 3: Poor Candidate (Not Recommended for LT)</h2>
                    <span class="case-badge">POOR CANDIDATE</span>
                </div>

                <div class="case-content">
                    <h3>Patient Presentation</h3>
                    <p><strong>Patient:</strong> 62-year-old male with extensive liver-only colorectal metastases</p>
                    
                    <div class="case-table">
                        <table class="data-table">
                            <tr>
                                <th>Parameter</th>
                                <th>Value</th>
                                <th>Significance</th>
                            </tr>
                            <tr>
                                <td><strong>Primary Tumor</strong></td>
                                <td>Rectum, T4N2M1 (18 months prior)</td>
                                <td>Node-positive, advanced primary</td>
                            </tr>
                            <tr>
                                <td><strong>Disease-Free Interval</strong></td>
                                <td>18 months</td>
                                <td>Short interval</td>
                            </tr>
                            <tr>
                                <td><strong>Metastases</strong></td>
                                <td>12+ liver lesions, largest 8.5 cm</td>
                                <td>Extensive disease burden</td>
                            </tr>
                            <tr>
                                <td><strong>CEA Level</strong></td>
                                <td>245 ng/mL</td>
                                <td>Markedly elevated</td>
                            </tr>
                            <tr>
                                <td><strong>Chemotherapy Response</strong></td>
                                <td>Progressive disease</td>
                                <td>Aggressive biology</td>
                            </tr>
                        </table>
                    </div>

                    <h3>Prognostic Assessment</h3>
                    <table class="data-table">
                        <tr>
                            <th>Scoring System</th>
                            <th>Score</th>
                            <th>Risk Category</th>
                            <th>Expected 5-Year OS</th>
                        </tr>
                        <tr class="unfavorable">
                            <td><strong>Oslo Score</strong></td>
                            <td>4</td>
                            <td>Unfavorable</td>
                            <td>8.3%</td>
                        </tr>
                        <tr class="unfavorable">
                            <td><strong>FCRS</strong></td>
                            <td>5</td>
                            <td>Unfavorable</td>
                            <td>< 10%</td>
                        </tr>
                        <tr class="unfavorable">
                            <td><strong>PET-MTV</strong></td>
                            <td>180 cm³</td>
                            <td>Unfavorable (>> 70)</td>
                            <td>< 10%</td>
                        </tr>
                    </table>

                    <h3>Molecular Profile</h3>
                    <ul>
                        <li><strong>BRAF:</strong> V600E mutation (✗ ABSOLUTE EXCLUSION)</li>
                        <li><strong>KRAS:</strong> G12C mutation</li>
                        <li><strong>TP53:</strong> R248Q mutation</li>
                        <li><strong>MSI:</strong> Microsatellite instability (✗ EXCLUSION)</li>
                        <li><strong>RAS/TP53 co-mutations:</strong> Present (very unfavorable)</li>
                    </ul>

                    <h3>Clinical Assessment</h3>
                    <div class="warning-box">
                        <h4>Multiple Exclusion Criteria Present:</h4>
                        <ul>
                            <li>✗ BRAF V600E mutation (absolute exclusion)</li>
                            <li>✗ Microsatellite instability (exclusion)</li>
                            <li>✗ RAS/TP53 co-mutations (very poor prognosis)</li>
                            <li>✗ Progressive disease on chemotherapy (aggressive biology)</li>
                            <li>✗ Markedly elevated CEA (extensive disease)</li>
                            <li>✗ Oslo Score 4 (worst prognostic category)</li>
                        </ul>
                    </div>

                    <h3>Treatment Decision</h3>
                    <div class="decision-box poor-decision">
                        <p><strong>Recommendation:</strong> NOT A CANDIDATE FOR LIVER TRANSPLANTATION</p>
                        <p><strong>Rationale:</strong> Multiple absolute and relative exclusion criteria. BRAF V600E mutation and microsatellite instability are absolute contraindications. RAS/TP53 co-mutations associated with median OS of only 21 months. Expected 5-year OS with LT would be < 10%. Patient would be better served by palliative care.</p>
                    </div>

                    <h3>Alternative Management</h3>
                    <p><strong>Recommended Approach:</strong> Palliative care with systemic chemotherapy</p>
                    <ul>
                        <li><strong>Chemotherapy:</strong> Continue FOLFOX or consider alternative regimen given progression</li>
                        <li><strong>Targeted Therapy:</strong> Consider sotorasib (KRAS G12C inhibitor) given mutation status</li>
                        <li><strong>Locoregional Therapy:</strong> TACE or SIRT for symptom control if needed</li>
                        <li><strong>Supportive Care:</strong> Palliative care team involvement; symptom management; quality of life focus</li>
                        <li><strong>Clinical Trials:</strong> Enrollment in trials for advanced CRLM if eligible</li>
                    </ul>

                    <p><strong>Follow-up (12 months):</strong></p>
                    <ul>
                        <li>Continued progression despite multiple chemotherapy regimens</li>
                        <li>Development of hepatic encephalopathy</li>
                        <li>Palliative care team managing symptoms</li>
                        <li>Patient and family focused on quality of life</li>
                    </ul>

                    <p><strong>Key Learning Point:</strong> Not all patients with CRLM are candidates for LT. Careful patient selection using prognostic scoring systems and molecular profiling is essential to identify patients who will benefit from transplantation and avoid offering futile treatment to those with poor prognosis.</p>
                </div>
            </section>

            <!-- Case 4: Excluded Candidate -->
            <section class="section case-study">
                <div class="case-header excluded">
                    <h2>Case 4: Excluded Candidate (Extrahepatic Disease)</h2>
                    <span class="case-badge">EXCLUDED</span>
                </div>

                <div class="case-content">
                    <h3>Patient Presentation</h3>
                    <p><strong>Patient:</strong> 55-year-old female with colorectal metastases to liver and lungs</p>
                    
                    <h3>Key Finding</h3>
                    <div class="warning-box">
                        <p><strong>Extrahepatic Metastases:</strong> Multiple bilateral pulmonary nodules (largest 2.5 cm)</p>
                        <p><strong>Exclusion Criterion:</strong> Extrahepatic metastases are an absolute contraindication for LT (except prior resected pulmonary metastases)</p>
                    </div>

                    <h3>Liver Disease Assessment</h3>
                    <ul>
                        <li><strong>Liver Metastases:</strong> 4 lesions, largest 3.5 cm (would be resectable)</li>
                        <li><strong>Oslo Score:</strong> 1 (favorable)</li>
                        <li><strong>FCRS:</strong> 0 (favorable)</li>
                        <li><strong>PET-MTV:</strong> 35 cm³ (favorable)</li>
                    </ul>

                    <h3>Treatment Decision</h3>
                    <div class="decision-box">
                        <p><strong>Recommendation:</strong> NOT A CANDIDATE FOR LIVER TRANSPLANTATION</p>
                        <p><strong>Rationale:</strong> Although liver disease is favorable, extrahepatic pulmonary metastases are an absolute exclusion criterion for LT. This patient should be considered for liver resection combined with pulmonary resection or locoregional therapy for lung lesions.</p>
                    </div>

                    <h3>Alternative Management</h3>
                    <ul>
                        <li><strong>Liver Resection:</strong> Hepatic resection of 4 metastases</li>
                        <li><strong>Pulmonary Management:</strong> Thoracoscopic resection of lung nodules</li>
                        <li><strong>Systemic Therapy:</strong> Adjuvant chemotherapy post-resection</li>
                    </ul>

                    <p><strong>Key Learning Point:</strong> Thorough staging with PET-CT is essential to identify extrahepatic disease. Even patients with excellent liver disease prognosis are not candidates for LT if extrahepatic metastases are present.</p>
                </div>
            </section>

            <!-- Case 5: Excellent Response to Bridging Therapy -->
            <section class="section case-study">
                <div class="case-header excellent">
                    <h2>Case 5: Transformation from Marginal to Excellent Candidate</h2>
                    <span class="case-badge">EXCELLENT RESPONSE TO BRIDGING</span>
                </div>

                <div class="case-content">
                    <h3>Initial Presentation</h3>
                    <p><strong>Patient:</strong> 54-year-old male with newly diagnosed unresectable CRLM</p>
                    
                    <table class="data-table">
                        <tr>
                            <th>Parameter</th>
                            <th>Initial</th>
                            <th>After 12 Months Bridging</th>
                        </tr>
                        <tr>
                            <td><strong>Largest Tumor</strong></td>
                            <td>7.2 cm</td>
                            <td>3.8 cm (47% reduction)</td>
                        </tr>
                        <tr>
                            <td><strong>CEA Level</strong></td>
                            <td>125 ng/mL</td>
                            <td>18 ng/mL (86% reduction)</td>
                        </tr>
                        <tr>
                            <td><strong>PET-MTV</strong></td>
                            <td>95 cm³</td>
                            <td>42 cm³ (56% reduction)</td>
                        </tr>
                        <tr>
                            <td><strong>Oslo Score</strong></td>
                            <td>3 (unfavorable)</td>
                            <td>1 (favorable)</td>
                        </tr>
                        <tr>
                            <td><strong>FCRS</strong></td>
                            <td>3 (unfavorable)</td>
                            <td>1 (favorable)</td>
                        </tr>
                    </table>

                    <h3>Bridging Therapy</h3>
                    <ul>
                        <li><strong>Regimen:</strong> FOLFOXIRI + bevacizumab</li>
                        <li><strong>Duration:</strong> 12 months (6 cycles)</li>
                        <li><strong>Response:</strong> Partial response with excellent tolerance</li>
                        <li><strong>Molecular Profile:</strong> BRAF wild-type, KRAS wild-type, TP53 wild-type, MSI negative</li>
                    </ul>

                    <h3>Transformation of Risk Profile</h3>
                    <div class="highlight-box">
                        <p><strong>Initial Assessment:</strong> Marginal/poor candidate based on unfavorable scoring systems and high disease burden</p>
                        <p><strong>After Bridging Therapy:</strong> Excellent candidate based on dramatic response and transformation to favorable prognostic profile</p>
                        <p><strong>Key Insight:</strong> Response to bridging chemotherapy is a dynamic prognostic factor. Patients with excellent response may be "upgraded" from poor to excellent candidates.</p>
                    </div>

                    <h3>Treatment Decision</h3>
                    <div class="decision-box">
                        <p><strong>Recommendation:</strong> PROCEED WITH LIVER TRANSPLANTATION</p>
                        <p><strong>Rationale:</strong> Excellent response to bridging therapy has transformed patient from marginal to excellent candidate. Current prognostic scores are favorable. Expected 5-year OS 75-85%.</p>
                    </div>

                    <h3>Outcome</h3>
                    <p><strong>Surgical Course:</strong> Deceased donor liver transplantation</p>
                    <ul>
                        <li><strong>Operative time:</strong> 4.8 hours</li>
                        <li><strong>Graft function:</strong> Excellent</li>
                        <li><strong>Hospital stay:</strong> 11 days</li>
                    </ul>

                    <p><strong>Follow-up (36 months post-LT):</strong></p>
                    <ul>
                        <li>No recurrence detected</li>
                        <li>Excellent graft function</li>
                        <li>Excellent quality of life</li>
                    </ul>

                    <p><strong>Key Learning Point:</strong> Extended bridging chemotherapy can dramatically improve prognostic scores and disease burden. Patients with excellent response to bridging therapy may achieve excellent long-term outcomes despite initially unfavorable presentation.</p>
                </div>
            </section>

            <section class="section call-to-action">
                <h2>Summary of Case Studies</h2>
                <p>These case studies illustrate the importance of:</p>
                <ul>
                    <li>Comprehensive prognostic assessment using multiple scoring systems</li>
                    <li>Molecular profiling to identify exclusion criteria</li>
                    <li>Careful patient selection to optimize outcomes</li>
                    <li>Extended bridging therapy for marginal candidates</li>
                    <li>Multidisciplinary team discussion for complex cases</li>
                    <li>Patient counseling about realistic expectations</li>
                </ul>
                <p>For more information on patient selection, visit the <a href="selection-criteria.html">Selection Criteria</a> page or use the <a href="tools.html">Interactive Tools</a> to assess patient eligibility.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765115033437"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
</body>
</html>
